APA (7th ed.) Citation

B, R., N, A. A., S, C. P., F, C., S, D., B, L., . . . M, F. (2025). Assessing the Safety and Efficacy of Lamotrigine as Anti-myotonic Agent in Myotonic Dystrophy Type 1 (DM1): A Longitudinal, Open-Label, Pilot Study. Neurology and therapy, 14(5), 2249. https://doi.org/10.1007/s40120-025-00804-z

Chicago Style (17th ed.) Citation

B, Risi, et al. "Assessing the Safety and Efficacy of Lamotrigine as Anti-myotonic Agent in Myotonic Dystrophy Type 1 (DM1): A Longitudinal, Open-Label, Pilot Study." Neurology and Therapy 14, no. 5 (2025): 2249. https://doi.org/10.1007/s40120-025-00804-z.

MLA (9th ed.) Citation

B, Risi, et al. "Assessing the Safety and Efficacy of Lamotrigine as Anti-myotonic Agent in Myotonic Dystrophy Type 1 (DM1): A Longitudinal, Open-Label, Pilot Study." Neurology and Therapy, vol. 14, no. 5, 2025, p. 2249, https://doi.org/10.1007/s40120-025-00804-z.